Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Harald StenmarkInst. Head
Harald Stenmark
Inst. Head

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
2017 so far  
 2016 235  15
2015 221 21
2014 174 25

Annual report 2016 (pdf):
download in single page format - double page (broad) format


Latest news

Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2017

Award winners during the ceremony (photo Pål Bakke)
Award winners during the ceremony (photo Pål Bakke)

Six research groups were awarded for their excellent papers published during the first half-year of 2017 during a ceremony on December 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.


OUH research seminar, Monday, December 4th 14:30

The challenges of discovering new antibiotics


Welcome to the next Oslo University Hospital (OUH) research seminar entitled:
The challenges of discovering new antibiotics

Time: Monday, December 4th at 14:30–16:00
Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo

Speakers: Kirsten Skarstad, Magnar Bjørås and Pål Rongved.


Alicia Llorente participates in an ERA-NET funded project

Alicie Llorente
Alicie Llorente

Alicia Llorente, project group leader at the Department of Molecular Cell Biology in the research group headed by Kirsten Sandvig, has recently received a grant to participate in a project funded by the Horizon2020 action ERA-NET TRANSCAN-2. TRANSCAN-2 is a collaborative network of ministries, funding agencies and research councils that aims to align national/regional translational cancer research programmes.
Both The Norwegian Research Council and The Norwegian Cancer Society participate in TRANSCAN-2. The project is funded by the Third Joint Transnational Call (JTC 2016) dedicated to "Minimally and non-invasive methods for early detection and/or progression of cancer". A total of 14 projects were funded under this call, and three of them have Norwegian participants.


Update: Nature Cell Biology paper draws attention:

Rusten group uncovers new regulatory mechanism of the Peutz-Jeghers cancer syndrome kinase, LKB1

Team at Centre for Cancer Biomedicine behind the study
Team at Centre for Cancer Biomedicine behind the study

Structural breakdown of epithelial architecture is a cardinal hallmark of carcinomas - the most common forms of cancer.
Our cells contain tumor suppressor genes that act as gate-keepers to prevent tumor growth. One such classical tumor suppressor, Liver Kinase B1 (LKB1), was identified as being responsible for the hereditary cancer predisposition syndrome, Peutz-Jeghers syndrome. It has later been shown to be mutated in other cancer types, such as lung cancer.
Reporting in the prestigeous journal Nature Cell Biology (IF 20,6), O´Farrell and colleagues now reports that intracellular endocytic trafficking of LKB1 is essential to curtail Lkb1 activity from going rogue. In a surprising twist, they show that LKB1 can act to promote carcinogenesis, a role normally possessed by oncogenes.

Update: PNAS has published a commentary article about the findings in their "Journal Club" section, where recently published papers selected by Academy members are highlighted. 


Young Investigator Prize to Anita Sveen during annual "Onkologisk Forum" meeting Nov 2017

Anita Sveen
Anita Sveen

Dr. Anita Sveen from Ragnhild Lothe's group at the Department of Molecular Oncology received the Young Investigator prize at Onkologisk Forum for her research accomplishments. This annual meeting for oncologists took place in Oslo on November 16-17. The award amounts to 50.000 NOK, to be spent on research.

Sveen presented her research in computational oncology, focusing on clinical relevant questions for colorectal cancer and novel results published in 6 selected papers.


Paper on novel pathway selected for inclusion in the ‘In This Issue’ section of Journal of Cell Science

Beata Grallert (left) and Christiane Rothe
Beata Grallert (left) and Christiane Rothe

Cell-cycle checkpoints are crucial for the maintenance of genomic integrity. The checkpoint operating in G2 phase of the cell cycle prevents entry into mitosis in the face of DNA damage. In cancer cells checkpoints are often deficient and thus they most likely rely on alternative pathways.
The authors describe a novel pathway for delayed entry into mitosis in response to DNA damage, which does not depend on the classic checkpoint pathways. Instead, the pathway involves selective translation regulation of a key mitotic regulator, cyclin B. This work is the first demonstration of selective translation regulation of a cell-cycle regulator in response to DNA-damage stress and raises the question whether similar pathways also exist in cancer cells with impaired checkpoints.
The findings are selected for the "In this issue" section in "Journal of Cell Science" on Dec 1st.